These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26874330)

  • 1. Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans.
    Maqueda AE; Valle M; Addy PH; Antonijoan RM; Puntes M; Coimbra J; Ballester MR; Garrido M; González M; Claramunt J; Barker S; Lomnicka I; Waguespack M; Johnson MW; Griffiths RR; Riba J
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26874330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans.
    Maqueda AE; Valle M; Addy PH; Antonijoan RM; Puntes M; Coimbra J; Ballester MR; Garrido M; González M; Claramunt J; Barker S; Johnson MW; Griffiths RR; Riba J
    Int J Neuropsychopharmacol; 2015 Jun; 18(12):. PubMed ID: 26047623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.
    Butelman ER; Mandau M; Tidgewell K; Prisinzano TE; Yuferov V; Kreek MJ
    J Pharmacol Exp Ther; 2007 Jan; 320(1):300-6. PubMed ID: 17060493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
    Valle M; Maqueda AE; Rabella M; Rodríguez-Pujadas A; Antonijoan RM; Romero S; Alonso JF; Mañanas MÀ; Barker S; Friedlander P; Feilding A; Riba J
    Eur Neuropsychopharmacol; 2016 Jul; 26(7):1161-75. PubMed ID: 27039035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.
    Fantegrossi WE; Kugle KM; Valdes LJ; Koreeda M; Woods JH
    Behav Pharmacol; 2005 Dec; 16(8):627-33. PubMed ID: 16286814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement.
    Braida D; Limonta V; Pegorini S; Zani A; Guerini-Rocco C; Gori E; Sala M
    Psychopharmacology (Berl); 2007 Mar; 190(4):441-8. PubMed ID: 17219220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of use and subjective effects of Salvia divinorum among recreational users.
    González D; Riba J; Bouso JC; Gómez-Jarabo G; Barbanoj MJ
    Drug Alcohol Depend; 2006 Nov; 85(2):157-62. PubMed ID: 16720081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.
    Johnson MW; MacLean KA; Reissig CJ; Prisinzano TE; Griffiths RR
    Drug Alcohol Depend; 2011 May; 115(1-2):150-5. PubMed ID: 21131142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.
    MacLean KA; Johnson MW; Reissig CJ; Prisinzano TE; Griffiths RR
    Psychopharmacology (Berl); 2013 Mar; 226(2):381-92. PubMed ID: 23135605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.
    Braida D; Capurro V; Zani A; Rubino T; Viganò D; Parolaro D; Sala M
    Br J Pharmacol; 2009 Jul; 157(5):844-53. PubMed ID: 19422370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antinociceptive effect of salvinorin A in mice.
    John TF; French LG; Erlichman JS
    Eur J Pharmacol; 2006 Sep; 545(2-3):129-33. PubMed ID: 16905132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward.
    Braida D; Limonta V; Capurro V; Fadda P; Rubino T; Mascia P; Zani A; Gori E; Fratta W; Parolaro D; Sala M
    Biol Psychiatry; 2008 Feb; 63(3):286-92. PubMed ID: 17920565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.
    Ranganathan M; Schnakenberg A; Skosnik PD; Cohen BM; Pittman B; Sewell RA; D'Souza DC
    Biol Psychiatry; 2012 Nov; 72(10):871-9. PubMed ID: 22817868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Learning and memory impairment induced by salvinorin A, the principal ingredient of Salvia divinorum, in wistar rats.
    Braida D; Donzelli A; Martucci R; Capurro V; Sala M
    Int J Toxicol; 2011 Dec; 30(6):650-61. PubMed ID: 21960665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.
    Liechti ME; Saur MR; Gamma A; Hell D; Vollenweider FX
    Neuropsychopharmacology; 2000 Oct; 23(4):396-404. PubMed ID: 10989266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects.
    Klaiber A; Schmid Y; Becker AM; Straumann I; Erne L; Jelusic A; Thomann J; Luethi D; Liechti ME
    Transl Psychiatry; 2024 Sep; 14(1):395. PubMed ID: 39349427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.
    Butelman ER; Rus S; Prisinzano TE; Kreek MJ
    Psychopharmacology (Berl); 2010 Jun; 210(2):253-62. PubMed ID: 20084367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics.
    Cruz A; Domingos S; Gallardo E; Martinho A
    Phytochemistry; 2017 May; 137():9-14. PubMed ID: 28190678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.
    Quednow BB; Kometer M; Geyer MA; Vollenweider FX
    Neuropsychopharmacology; 2012 Feb; 37(3):630-40. PubMed ID: 21956447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.
    Carter OL; Burr DC; Pettigrew JD; Wallis GM; Hasler F; Vollenweider FX
    J Cogn Neurosci; 2005 Oct; 17(10):1497-508. PubMed ID: 16269092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.